Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.

February 21, 2025

Vol.51 No.07

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

Black History Month Podcast The Directors

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

Is the Community Outreach and Engagement mandate the next item on the chopping block as the Trump administration makes its mark on science policy? What about health disparities research?

February 14, 2025

Vol.51 No.06

By Paul Goldberg

Cancer History Project Podcast

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.

February 14, 2025

Vol.51 No.06

By Yiqing Wang

Clinical Roundup

Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

February 07, 2025

Vol.51 No.05

Clinical Roundup

DFCI researchers use PET imaging to detect body inflammation

Researchers at Dana-Farber Cancer Institute developed a method to detect inflammation in the body using positron emission tomography imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types.

January 24, 2025

Vol.51 No.03

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

YOU MAY BE INTERESTED IN

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer

DFCI researchers use PET imaging to detect body inflammation

Renew today!

Subscriber content

Never miss an issue!

Login

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

YOU MAY BE INTERESTED IN

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centersThe Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty

20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect

Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer

DFCI researchers use PET imaging to detect body inflammation

Never miss an issue!

Login

On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty